Neuropsychopharmacology Pharmacology

Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →